ERBB2 and breast carcinoma: The addition of anti-HER2 therapy to the neoadjuvant management of early-stage HER2-positive breast cancer has yielded substantial clinical benefits, dramatically improving patient outcomes in HER2-positive (HER2+) early breast cancer, as recently proven by the 2021 EBCTCG (Early Breast Cancer Trialists’ Collaborative Group) meta-analysis of Trastuzumab in HER2-positive early breast cancer [17,18].